Envista (NVST)

• Market cap: $3.13B
• 1 day: -2.23%
• 5 days: -2.54%
• 1 month: -0.86%
• 3 months: 13.54%
• 6 months: -5.24%
• Year to date: -3.45%
• 1 year: 3.48%
• 5 years: -11.60%
• 10 years: -33.99%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Employees: 12,300

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 87

10% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 42

1% less funds holding

Funds holding: 287 [Q4 2024] → 285 (-2) [Q1 2025]

1.28% less ownership

Funds ownership: 113.25% [Q4 2024] → 111.97% (-1.28%) [Q1 2025]

12% less capital invested

Capital invested by funds: $3.76B [Q4 2024] → $3.33B (-$433M) [Q1 2025]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 2 (-3) [Q1 2025]

81% less call options, than puts

Call options by funds: $929K | Put options by funds: $4.99M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 8% downside
• Avg. target: $20 10% upside
• High target: $23 25% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Baird Jeff Johnson	25% upside $23	Outperform Upgraded	27 May 2025
UBS Kevin Caliendo	2% downside $18	Neutral Maintained	5 May 2025
Piper Sandler Jason Bednar	8% downside $17	Neutral Maintained	30 Apr 2025
B of A Securities Michael Cherny	25% upside $23	Buy Maintained	29 Apr 2025